OBJECTIVE

To evaluate the effectiveness of the drug aminodihydrophthalazinedione sodium (Galavit) for the prevention of the development of additional purulent-septic complications associated with a reduced reactivity in patients with peritonitis.

MATERIAL AND METHODS

Patients diagnosed with peritonitis were included in a prospective, non-randomized, single-centre study. Two groups of patients were formed, the main and control, 30 people each. In the main group, patients received aminodihydrophthalazinedione sodium at a dose of 100 mg/day for 10 days, in the control group they did not receive the drug. During 30 days of observation, the development of purulent-septic complications and the number of days of hospitalization were recorded. Biochemical and immunological blood parameters were recorded at the time of inclusion in the study and for 10 days of therapy. Information about adverse events were collected.

RESULTS

Each study group included 30 patients (60 in total). The additional complications developed in 3 (10%) patients who received the drug and in 7 (23.3%) in the group that did not receive the drug (p=0.166). The risk ratio is up to 0.556 and the risk ratio is 0.365. The average number of bed-days in the group that received the drug was 5, and in the group that did not receive the drug — 7 days (p=0.108). No statistically significant differences between groups in biochemical parameters were identified. However, there were estimated statistical differences in immunological parameters. Thus, CD3+, CD4+, CD19+, CD16+/CD56+, CD3+/HLA-DR+, IgG were higher in the group taking the drug, and the CIC level was lower than in patients of the group that did not receive the drug. There were no adverse events.

CONCLUSION

Aminodihydrophthalazinedione sodium (Galavit) is effective and safe for preventing the development of additional purulent-septic complications associated with a reduced reactivity in patients with peritonitis, decreases the incidence of purulent-septic complications.